2 Beaten-Down Dividend Growth Stocks to Buy on the Dip

Core Insights - The current stock market is reaching all-time highs, which is challenging for investors seeking passive income due to low dividend yields [1] Novo Nordisk - Novo Nordisk's stock has decreased by 56% from its peak due to competition from compounding pharmacies and disappointing results from an experimental treatment [5][8] - The company has a strong history of dividend growth, with a 129% increase in its ordinary dividend and a 105% increase in its interim dividend over the past five years [6] - At recent prices, Novo Nordisk offers a yield of 2.5%, which is more than double the average yield of 1.2% for S&P 500 dividend stocks [7] - The FDA's decision to stop allowing compounding pharmacies to sell their own versions of semaglutide is expected to positively impact Novo Nordisk's sales moving forward [10] - The stock is currently trading at 16 times forward-looking earnings estimates, which is considered low given the company's growth potential [11] UnitedHealth Group - UnitedHealth Group's stock has fallen about 55% from its peak due to underestimating rising healthcare expenses [12] - The company has raised its dividend payout by 77% over the past five years, indicating a strong commitment to returning value to shareholders [13] - Despite recent challenges, UnitedHealth is positioned to pass increasing healthcare costs onto customers, which may stabilize earnings in the future [14] - The upcoming earnings guidance announcement is critical for restoring investor confidence, but dividends will continue to be paid during this period [15]